Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
- MHLW, Pharma Industry Officials Agree on Conditional Early Approval System
January 31, 2017
- Shiozaki Calls for Enactment of Clinical Research Bill ASAP
January 30, 2017
- MHLW Committee to Discuss Shionogi’s OIC Drug on Feb. 9
January 27, 2017
- Govt’s Bleak Primary Deficit Outlook to Weigh Further on Social Securities
January 26, 2017
- AMED to Collaborate with UK Funding Agency, Open London Office
January 26, 2017
- MHLW Lays Out Chuikyo Discussion Timeline for Drug Pricing Overhaul
January 26, 2017
- Industry Wants Simplified Rule, Limited Application for Foreign Price Adjustment: Chuikyo
January 26, 2017
- Chuikyo on Alert for Trump’s Possible Pressure on Drug Front
January 26, 2017
- MHLW Warns Against Purchasing Harvoni in Unpackaged Bottles
January 26, 2017
- MHLW Presents Draft Optimal Use Guidelines for Keytruda: Chuikyo
January 25, 2017
- (Update) Chuikyo Agrees to Shed US Price from Foreign Price Adjustment Rule
January 25, 2017
- Boy Develops ADEM after DT Vaccine Shot, No Label Change for Now: Panel
January 25, 2017
- MHLW to Launch New Framework for Dialogue with Pharma Industry
January 24, 2017
- Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle
January 24, 2017
- MHLW Advisory Committee to Review Sanofi’s VEGF Inhibitor on Feb. 3
January 24, 2017
- PMDA Risk Communication Update for Atarax, Zelboraf
January 23, 2017
- MHLW Asks Pref. Govt to Conduct On-Site Inspections for Pharmacies, Wholesalers: Minister
January 23, 2017
- Correcting Regional Disparities in Generic Use Important for Achieving Govt’s Targets: Health Policy Bureau Chief
January 23, 2017
- Counterfeit Harvoni Likely Entered Distribution before Reaching Pharmacies: MHLW Official
January 23, 2017
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…